Risk Factors for Gastrointestinal and Hepatic Adverse Reactions in Rheumatoid Arthritis Patients on Biologic and Conventional DMARDs
Adverse Reactions in Rheumatoid Arthritis
DOI:
https://doi.org/10.69750/dmls.01.08.074Keywords:
Rheumatoid arthritis, DMARDs, biologic DMARDs, gastrointestinal adverse reactions, hepatic adverse reactions, risk factors, biomarkersAbstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease treated with disease modifying antirheumatic drugs (DMARDs), which includes conventional synthetic (csDMARDs) and biologic (bDMARDs) agents, and are associated with adverse drug reactions (ADRs) in the gastrointestinal (GI) and hepatobiliary systems.
Objectives: In RA patients on combination of biologic and conventional DMARD therapies to identify risk factors associated with GI and hepatic ADRs.
Methods: We conducted a multi-centre, observational, retrospective study of 500 RA patients treated with csDMARDs, bDMARDs, or in combination of both. Demographics, biomarkers and clinical profiles were collected. Patient characteristics, treatment types and ADR occurrence were monitored over 24 weeks and statistical analysis was performed to find a correlation between patient characteristics, treatment types, and the occurrence of ADRs. Significant associations were identified with logistic regression and chi-square tests.
Results: 24.2% of patients had an ADR, with GI ADRs accounting for 16.6% and hepatic ADRs for 9.1%. Compared to csDMARDs, users (4.2%), bDMARDs users (13.8%) had hepatic ADRs more frequently (p < 0.01). High CRP levels decreased the risk of GI ADRs, but elevated IgG levels raised the risk of hepatic ADRs. Both ADR kinds were predicted by systemic symptoms.
Conclusion: Biologic DMARDs present a higher risk of hepatic ADRs in RA patients compared to conventional DMARDs. Key predictors of ADRs include elevated IgG levels and systemic symptoms, underscoring the need for close monitoring of biomarkers and patient-reported symptoms to mitigate adverse events during DMARD therapy.
Downloads
References
Jiang M, Zha Q, He Y, Lu A. Risk factors of gastrointestinal and hepatic adverse drug reactions in the treatment of rheumatoid arthritis with biomedical combination therapy and Chinese medicine. Journal of Ethnopharmacology. 2012;141(2):615-21.doi: https://doi.org/10.1016/j.jep.2011.07.026
Zekić T, Benić MS, Radić M. Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease. Rheumatology International. 2022;42(10):1665-79.doi: 10.1007/s00296-022-05143-y
Ma SN, Zaman Huri H, Yahya F. Drug-related problems in patients with rheumatoid arthritis. Therapeutics and Clinical Risk Management. 2019;15(null):505-24.doi: 10.2147/TCRM.S194921
Sah SK, Ramaswamy S, Ramesh M. “Assessment of potential drug-drug interactions and their associated risk factor in patients with rheumatoid arthritis: A cross-sectional study”. Clinical Epidemiology and Global Health. 2023;23:101373.doi: https://doi.org/10.1016/j.cegh.2023.101373
Sherbini AA, Gwinnutt JM, Hyrich KL, Co-Investigators R, Verstappen SMM. Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology. 2022;61(10):3930-8.doi: 10.1093/rheumatology/keab917
Costello R, David T, Jani M. Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis. Clinical Therapeutics. 2019;41(7):1376-96.doi: https://doi.org/10.1016/j.clinthera.2019.04.030
Dubey L, Chatterjee S, Ghosh A. Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study. Indian Journal of Pharmacology. 2016;48(5):591-4.doi: 10.4103/0253-7613.190761
Min HK, Kim SH, Kim H-R, Lee S-H. Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis. International Journal of Molecular Sciences [Internet]. 2022; 23(22).doi: 10.3390/ijms232213913
Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nature Reviews Rheumatology. 2011;7(11):639-52.doi: 10.1038/nrrheum.2011.145
Chiu Y-M, Chen D-Y. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Review of Clinical Immunology. 2020;16(2):207-28.doi: 10.1080/1744666X.2019.1705785
Díaz-Borjón A. Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis. Drugs & Aging. 2009;26(4):273-93.doi: 10.2165/00002512-200926040-00001
Avalos-Salgado FA, Gonzalez-Lopez L, Gonzalez-Vazquez S, Ponce-Guarneros JM, Santiago-Garcia AP, Amaya-Cabrera EL, et al. Risk Factors Associated with Adverse Events Leading to Methotrexate Withdrawal in Elderly Rheumatoid Arthritis Patients: A Retrospective Cohort Study. Journal of Clinical Medicine [Internet]. 2024; 13(7).doi: 10.3390/jcm13071863
Castro CTd, Queiroz MJd, Albuquerque FC, Brandão CC, Gerlack LF, Pereira DCR, et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis. Frontiers in Pharmacology. 2022;13.doi: 10.3389/fphar.2022.927179
Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opinion on Biological Therapy. 2017;17(9):1089-103.doi: 10.1080/14712598.2017.1346078
Kitamura N, Kobayashi H, Nagasawa Y, Sugiyama K, Tsuzuki H, Tanikawa Y, et al. Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy. International Journal of Rheumatic Diseases. 2023;26(6):1058-66.doi: https://doi.org/10.1111/1756-185X.14695
Nooh N, Lwin MN, Edwards C. Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis. Expert Opinion on Biological Therapy.1-9.doi: 10.1080/14712598.2024.2404521
Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International. 2020;40(4):511-21.doi: 10.1007/s00296-020-04526-3
Honma T, Onda K, Masuyama K. Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use. BMC Pharmacology and Toxicology. 2024;25(1):13.doi: 10.1186/s40360-024-00738-6
Atzeni F, Talotta R, Nucera V, Marino F, Gerratana E, Sangari D, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Review of Clinical Immunology. 2018;14(11):945-56.doi: 10.1080/1744666X.2018.1504678
Zhao X, Zhang C, An Y, Zhang Z, Zhao J, Zhang X, et al. Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents. Journal of Inflammation Research. 2023;16(null):443-52.doi: 10.2147/JIR.S395137
Cai W, Gu Y, Cui H, Cao Y, Wang X, Yao Y, et al. The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis. Frontiers in Pharmacology. 2018;9.doi: 10.3389/fphar.2018.00138
Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2020;79(6):760.doi: 10.1136/annrheumdis-2019-216653
Akhlaghi S, Sahebari M, Mahmoodi M, Yaseri M, Mansournia MA, Rafatpanah H, et al. Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study. Therapeutics and Clinical Risk Management. 2018;14(null):1943-50.doi: 10.2147/TCRM.S172836
Downloads
PlumX Metrics
Published
Issue
Section
License
Copyright (c) 2024 DEVELOPMENTAL MEDICO-LIFE-SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
